An Economic Review of Compliance With Medication Therapy in the Treatment of Schizophrenia

Abstract

A definitive relationship exists between compliance and the economic costs of schizophrenia. Lower rates of compliance lead to higher costs of treating schizophrenia. However, the full implications are difficult to surmise from the literature because of inadequacies in the reporting of compliance rates and outcomes of treatment over time. The authors suggest collection of data on longer-term clinical outcomes as a means to improve future economic evaluations of schizophrenia treatments.

Factors associated with relapse in schizophrenia

“…31 We observed an overall adherence rate of 64.2%, which concurs with other reported adherence rates. [32][33][34][35] However, this finding must be qualified in that self-reports of adherence are not always reliable. 31 The factors associated with poor adherence to treatment in the diagnostic group under review were medication side-effects and lack of insight.…”

Adesão em esquizofrenia

“…Fatores socioeconômicos também devem ser considerados (Thieda et al, 2003). Nos Estados Unidos, o custo anual total estimado para admissões hospitalares de curto prazo (menor ou igual a 90 dias) para recaídas de esquizofrenia é de Us$ 2,3 bilhões e o custo de readmissões é de Us$ 2 bilhões.…”

Observational study to assess prescription cost and its relation to the socioeconomic status of the patients in psychiatry outpatient department in a tertiary care hospital

“…15,16 Non adherence to medication in patients with mental disorders can increase the chances of relapse and longer stay in hospitals resulting increased cost to the patients. 17 In mental disorders, terms such as direct costs and indirect costs are used when healthcare economics are discussed. Direct costs mainly include fees paid to the doctor, cost of commuting to and from the hospital and cost of medications for mental disorders.…”